Cell Signaling Technology Logo - Extra Large
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

FGL1 (E7C1Q) Rabbit Monoclonal Antibody #73617

Filter:
  • WB
  • IHC
  • IF
  • F

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 32
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IHC-Immunohistochemistry 
    • IF-Immunofluorescence 
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunohistochemistry (Paraffin) 1:200 - 1:400
    Immunofluorescence (Immunocytochemistry) 1:200 - 1:800
    Flow Cytometry (Fixed/Permeabilized) 1:100 - 1:400

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    For a carrier free (BSA and azide free) version of this product see product #94562.

    Protocol

    Specificity / Sensitivity

    FGL1 (E7C1Q) Rabbit Monoclonal Antibody recognizes endogenous levels of total FGL1 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant human FGL1 protein.

    Background

    FGL1 (fibrinogen-like protein 1, also known as hepassocin) is a secreted protein mainly expressed in liver and its expression is further enhanced following acute liver injury (1-3). FGL1 mice have multiple metabolic abnormalities and are more prone to develop hepatocellular carcinoma under certain experimental conditions, suggesting FGL1 has diverse functions in vivo (4,5). More recently, FGL1 was found to be highly expressed in human cancer cells and function as an inhibitory ligand for LAG3. Blockade of the FGL1-LAG3 interaction stimulates tumor immunity in mouse models. In addition, a high plasma FGL1 level in human cancer patients is associated with a poor prognosis and resistance to anti-PD-1/PD-L1 immunotherapy (6).

    Alternate Names

    FGL1; fibrinogen like 1; fibrinogen-like 1; Fibrinogen-like protein 1; Hepassocin; hepatocellular carcinoma-related sequence; Hepatocyte-derived fibrinogen-related protein 1; HFREP-1; HFREP1; HP-041; HPS; LFIRE-1; LFIRE1; Liver fibrinogen-related protein 1; MGC12455

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.